Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Acumen Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEWTON, MASS., AUG. 26, 2025 (GLOBE NEWSWIRE) -- ACUMEN PHARMACEUTICALS, INC. (NASDAQ: ABOS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL THERAPEUTICS THAT TARGET TOXIC SOLUBLE AMYLOID BETA OLIGOMERS FOR THE TREATMENT OF ALZHEIMER'S DISEASE, ANNOUNCED TODAY THAT MANAGEMENT WILL PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES.

ACUMEN PHARMACEUTICALS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

NEWTON, MASS., AUG. 12, 2025 (GLOBE NEWSWIRE) -- ACUMEN PHARMACEUTICALS, INC. (NASDAQ: ABOS) (ACUMEN OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL THERAPEUTICS THAT TARGET TOXIC SOLUBLE AMYLOID BETA OLIGOMERS (AOS) FOR THE TREATMENT OF ALZHEIMER'S DISEASE (AD), TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2025 AND PROVIDED A BUSINESS UPDATE.

ACUMEN PHARMACEUTICALS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTSAND BUSINESS HIGHLIGHTS

NEWTON, MASS., AUG. 05, 2025 (GLOBE NEWSWIRE) -- ACUMEN PHARMACEUTICALS, INC. (NASDAQ: ABOS) (ACUMEN OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING A NOVEL THERAPEUTIC THAT TARGETS TOXIC SOLUBLE AMYLOID BETA OLIGOMERS FOR THE TREATMENT OF ALZHEIMER'S DISEASE, TODAY ANNOUNCED THAT THE COMPANY WILL REPORT SECOND QUARTER 2025 FINANCIAL RESULTS ON TUESDAY, AUGUST 12, 2025. THE COMPANY WILL HOST A CONFERENCE CALL AND LIVE AUDIO WEBCAST AT 8:00 A.M. ET TO PROVIDE A BUSINESS AND FINANCIAL UPDATE.

ACUMEN PHARMACEUTICALS TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS ON AUGUST 12, 2025

HYOGO, JAPAN--(BUSINESS WIRE)--JCR PHARMACEUTICALS CO., LTD. (TSE 4552; JCR), A GLOBAL SPECIALTY BIOPHARMACEUTICAL COMPANY DEDICATED TO DEVELOPING THERAPIES FOR RARE AND GENETIC DISEASES, TODAY ANNOUNCED A JOINT COLLABORATION, OPTION AND LICENSE AGREEMENT WITH ACUMEN PHARMACEUTICALS TO DEVELOP A NOVEL THERAPEUTIC CANDIDATE FOR THE TREATMENT OF ALZHEIMER'S DISEASE (AD), ENABLED BY JCR'S PROPRIETARY BLOOD-BRAIN BARRIER (BBB)-PENETRATING TECHNOLOGY PLATFORM, J-BRAIN CARGO. THE COLLABORATION FOCUS.

JCR PHARMACEUTICALS AND ACUMEN PHARMACEUTICALS ANNOUNCE COLLABORATION TO DEVELOP THERAPY FOR ALZHEIMER'S DISEASE, ENABLED BY J-BRAIN CARGO TECHNOLOGY PLATFORM

NEWTON, MASS., JULY 10, 2025 (GLOBE NEWSWIRE) -- ACUMEN PHARMACEUTICALS, INC.(NASDAQ: ABOS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING A NOVEL THERAPEUTIC THAT TARGETS SOLUBLE AMYLOID BETA OLIGOMERS (AOS) FOR THE TREATMENT OF ALZHEIMER'S DISEASE (AD),WILL PRESENT NEW FINDINGS AT THE UPCOMING ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2025 IN TORONTO. THE PRESENTATIONS INCLUDE A COST SAVINGS ANALYSIS OF THE USE OF PTAU217 AS A SCREENING TOOL IN ACUMEN'S PHASE 2 ALTITUDE-AD TRIAL OF SABIRNETUG AS WELL AS A NONCLINICAL STUDY EVALUATING THE RELATIVE SELECTIVITY OF SABIRNETUG TO TARGETING AOS VERSUS A MONOMERS. THE CONFERENCE WILL BE HELD JULY 27-31, 2025, BOTH IN-PERSON AND ONLINE.

ACUMEN PHARMACEUTICALS TO PRESENT STUDIES ON COST SAVINGS ASSOCIATED WITH USE OF PTAU217 SCREENING ASSAY IN PHASE 2 ALTITUDE-AD STUDY AND SABIRNETUG OLIGOMER-SELECTIVITY AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2025

NEWTON, MASS., MAY 07, 2025 (GLOBE NEWSWIRE) -- ACUMEN PHARMACEUTICALS, INC. (NASDAQ: ABOS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING A NOVEL THERAPEUTIC THAT TARGETS TOXIC SOLUBLE AMYLOID BETA OLIGOMERS FOR THE TREATMENT OF ALZHEIMER'S DISEASE, ANNOUNCED TODAY THAT MANAGEMENT WILL PARTICIPATE IN IN A FIRESIDE CHAT AT THE BANK OF AMERICAN HEALTHCARE CONFERENCE ON WEDNESDAY, MAY 14, 2025, AT 8:15 A.M. PT/11:15 A.M. ET.

ACUMEN PHARMACEUTICALS TO PARTICIPATE IN THE BANK OF AMERICA HEALTHCARE CONFERENCE

NEWTON, MASS., MAY 06, 2025 (GLOBE NEWSWIRE) -- ACUMEN PHARMACEUTICALS, INC. (NASDAQ: ABOS) (ACUMEN OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING A NOVEL THERAPEUTIC THAT TARGETS TOXIC SOLUBLE AMYLOID BETA OLIGOMERS FOR THE TREATMENT OF ALZHEIMER'S DISEASE, TODAY ANNOUNCED THAT THE COMPANY WILL REPORT FIRST QUARTER 2025 FINANCIAL RESULTS ON TUESDAY, MAY 13, 2025. THE COMPANY WILL HOST A CONFERENCE CALL AND LIVE AUDIO WEBCAST AT 8:00 A.M. ET TO PROVIDE A BUSINESS AND FINANCIAL UPDATE.

ACUMEN PHARMACEUTICALS TO REPORT FIRST QUARTER 2025 FINANCIAL RESULTS ON MAY 13, 2025

BIOMARKER RESULTS FROM PHASE 1 INTERCEPT-AD TRIAL OF SABIRNETUG IN PATIENTS WITH EARLY ALZHEIMER'S DISEASE RECENTLY PUBLISHED IN THE JOURNAL OF PREVENTION OF ALZHEIMER'S DISEASE BIOMARKER RESULTS FROM PHASE 1 INTERCEPT-AD TRIAL OF SABIRNETUG IN PATIENTS WITH EARLY ALZHEIMER'S DISEASE RECENTLY PUBLISHED IN THE JOURNAL OF PREVENTION OF ALZHEIMER'S DISEASE

ACUMEN PHARMACEUTICALS SHOWCASES PTAU217 TRIAL SCREENING PROGRESS IN PHASE 2 ALTITUDE-AD TRIAL AND PRECLINICAL RESEARCH METHODS AT AD/PD 2025 AND AAN ANNUAL MEETING

NEWTON, MASS., MARCH 20, 2025 (GLOBE NEWSWIRE) -- ACUMEN PHARMACEUTICALS, INC. (NASDAQ: ABOS) (ACUMEN OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING A NOVEL THERAPEUTIC THAT TARGETS TOXIC SOLUBLE AMYLOID BETA OLIGOMERS FOR THE TREATMENT OF ALZHEIMER'S DISEASE, TODAY ANNOUNCED THAT THE COMPANY WILL REPORT FOURTH QUARTER AND YEAR-END 2024 FINANCIAL RESULTS ON THURSDAY, MARCH 27, 2025. THE COMPANY WILL HOST A CONFERENCE CALL AND LIVE AUDIO WEBCAST AT 8:00 A.M. ET TO PROVIDE A BUSINESS AND FINANCIAL UPDATE.

ACUMEN PHARMACEUTICALS TO REPORT FOURTH QUARTER AND YEAR-END 2024 FINANCIAL RESULTS ON MARCH 27, 2025

NEW YORK, MARCH 18, 2025 (GLOBE NEWSWIRE) -- TODAY'S MARKETPLACE (TMP) IS PROUD TO ANNOUNCE A FEATURED INTERVIEW WITH ACUMEN PHARMACEUTICALS (NASDAQ: ABOS) CEO DANIEL O ' CONNELL AND JESSICA CLARK, DNP, RN, DEAN OF THE COLLEGE OF NURSING AT CREIGHTON UNIVERSITY. THE PAIR JOINED TODAY'S MARKETPLACE HOST ELIZABETH HART TO DISCUSS ALZHEIMER'S DISEASE.

Acumen Pharmaceuticals, Inc.

ABOS

Price

Financial Reports

No items found.

Press Releases

Acumen Pharmaceuticals, Inc.

ABOS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ABOS